Ocuphire Posts Second Phase III Success In Reversing Pupil Dilation

Nyxol is almost set for an NDA filing for reversal of dilation during eye exams/surgery. The reformulation of phentolamine is also being studied in presbyopia, setting up possible competition with AbbVie’s Vuity.

Eye exam
Ocuphire hopes Nyxol will prove a popular option with eye exam patients • Source: Alamy

Ocuphire Pharma, Inc. reported statistical significance for its eye drop candidate Nyxol in a second pivotal Phase III study in reversal of pharmacologically induced mydriasis (or pupil dilation). Management told investors on a 29 March call that the company anticipates filing the candidate for approval at the US Food and Drug Administration later this year.

There is no approved drug therapy for eye dilation that is induced pharmacologically during a routine eye exam or eye...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D